| Literature DB >> 36003336 |
Jiao Wang1,2, Li-Hai Zhang1,2, Yu-Ming Kang1, Xian-He Wang2, Chun-Yu Jiang2.
Abstract
The dysfunction of islet β-cells is one of the causes of diabetes, and lncRNA Gm10451 is also a participant in the occurrence and the development of various diseases. This study was carried out to reveal the correlation within β-cells and Gm10451. Our study was started with the cellular cultivation of MIN6 cells in vitro, where this islet β-cell line was randomly divided into the groups of control, hyperglycemia, Gm10451 siRNA tansfection, and Gm10451 tansfection. Of all these treatments, cells in the groups of Gm10451 siRNA tansfection and Gm10451 tansfection were given with lentiviral transfection under hyperglycemia condition. Further explorations were established using PCR assay and MTT method to evaluate Gm10451 expression and estimate cellular proliferation. It ended up with the enzyme-linked immunosorbent assay (ELISA) to assess Caspase 3 activity, superoxide dismutase (SOD) activity, and reactive oxygen species (ROS) content and the secretion of IL-10 and IL-1. It was found that Gm10451 expression in MIN6 cells under hyperglycemia cultivation was notably higher than the control group; likewise, a transfection with the lentivirus of Gm10451 also resulted in the upregulation of Gm10451 expression, succeeded with inhibiting cellular proliferation, enhancing Caspase 3 activity, and decreasing SOD activity. In the lentivirus transfection groups, transfection of Gm10451 elevated the ROS content and promoted IL-1 expression, and it also decreased both IL-10 expression and insulin secretion, leading to a consequence of statistically significant difference in contrast to the high-glucose group; on the contrary, transfection of Gm10451 siRNA in a high-glucose environment downregulated the expression of Gm10451 and inversed those change before, whose results were statistically significant when compared with the high-glucose group. Hyperglycemia promotes the expression of Gm10451. Targeting inhibition toward Gm10451 alleviates cellular apoptosis and the oxidative stress of islet cells, promoting proliferation and insulin secretion of islet cells.Entities:
Keywords: Gm10451; Gm10451 causes islet cell dysfunction lncRNA; diabetes; insulin; islet
Year: 2022 PMID: 36003336 PMCID: PMC9393641 DOI: 10.3389/fgene.2022.927471
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.772
FIGURE 1Gm10451 expression levels of MIN6 cells in the hyperglycemic environment. (A) Determination on Gm10451 expression in MIN6 cells under hyperglycemia by qPCR assay. (B) Determination on the Gm10451 expression level in Gm10451 over-expressed MIN6 cells by qPCR assay. (C) Determination on the Gm10451 expression level in Gm10451-interfered MIN6 cells by qPCR assay. (D) Gm10451s localization in MIN6 cells was pinpointed by FISH test. N = 3. **, p < 0.01.
FIGURE 2High levels of Gm10451 hindered MIN6 cell proliferation. (A,B) Assessment on MIN6 cell proliferation via Edu. (C) Assessment on MIN6 cell proliferation via MTT. N = 3. **, p < 0.01.
FIGURE 3Highly expressing Gm10451 promoted MIN6 cell apoptosis. (A,B) Determination on apoptosis of MIN6 cells using TUNEL assay. (C) Determination on apoptosis-related proteins’ expression through qPCR. N = 3. **, p < 0.01.
FIGURE 4High levels of Gm10451 increased the secretion of inflammatory factors. The expression levels of IL-10 and IL-1 were determined by ELISA. (A) Determination on IL-10 expression using the ELISA method. (B) Determination on IL-1 expression using the ELISA method. N = 3. **, p < 0.01.
FIGURE 5Gm10451 expression affects the insulin secretion and the REDOX reaction of the MIN6 cells cultured in the hyperglycemia environment. (A) Determination on the insulin content in MIN6 cells. (B) Determination on the SOD content. (C) Determination on the ROS content. N = 3. **, p < 0.01.